What is the difference between mcg, mg, and IU in peptide dosing?

Micrograms (mcg or μg) and milligrams (mg) are metric mass units: 1 mg = 1,000 mcg. Most research peptides are dosed in the mcg range (100–1,000 mcg typical) rather than the mg range. IU (International Units) is a biological activity measurement used for insulin and some vitamins — it does not apply to most research peptides. The confusion arises because insulin syringes (marked in "units" where 100 units = 1 mL) are commonly used to inject peptides, but the syringe markings measure volume (0.01 mL per unit), not peptide mass. A researcher must calculate the appropriate volume based on their specific peptide concentration.

How do I calculate the correct injection volume for my desired dose?

Use this formula: Injection volume (mL) = Desired dose (mcg) / Concentration (mcg/mL). For example, if your concentration is 2,500 mcg/mL and your desired dose is 250 mcg: 250 / 2,500 = 0.1 mL. On a U-100 insulin syringe (where 100 units = 1 mL), this equals 10 units. Always verify your concentration calculation first: Concentration (mcg/mL) = Vial mass (mg) × 1,000 / Reconstitution volume (mL).

Why are peptide doses measured in micrograms rather than milligrams?

Peptides are biologically active at much lower masses than small-molecule drugs. This reflects their mechanism: peptides bind to specific cell-surface receptors with high affinity, triggering signaling cascades at very low occupancy rates. A typical receptor-binding peptide may produce a maximal biological response when fewer than 10% of available receptors are occupied — a phenomenon known as receptor reserve. This means only a small number of peptide molecules (micrograms) are needed to activate a large downstream response. Small-molecule drugs, by contrast, often require milligram quantities because they work through enzyme inhibition or other mechanisms that demand higher molar concentrations.

Does subcutaneous injection lose some of the dose?

Yes — subcutaneous bioavailability is rarely 100%. For many peptides and proteins, a meaningful fraction of the administered dose may be degraded locally, bind tissue, or clear via lymph before reaching systemic circulation, and the magnitude varies with injection site and formulation [PMID: 34186147]. Published SC dose ranges already reflect that route. Consistency of technique, site, and depth across experimental groups is more important than chasing a theoretical 100% absorption figure.

What is the maximum volume I can inject subcutaneously?

Parenteral literature on injection-site pain and absorption treats volume as a major local factor. Practical guidance commonly keeps subcutaneous volumes near or below about 1–1.5 mL per site to limit pain, swelling, and absorption variability [PMID: 31587143]. If a dose requires a larger volume at standard concentration, options include: (1) increase concentration with less reconstitution solvent, (2) split across two injection sites, or (3) use an intramuscular site that can tolerate larger volumes when the protocol allows.

How do I convert a dose from a rodent study to a human-equivalent dose?

Simple mg/kg scaling does not work for interspecies dose conversion because metabolic rate, body surface area, and clearance rates scale allometrically — not linearly — with body mass. The FDA recommends body surface area (BSA) normalization using the formula: Human equivalent dose (mg/kg) = Animal dose (mg/kg) × (Animal Km / Human Km), where Km = body weight / BSA. For common research animals: mouse Km = 3, rat Km = 6, human Km = 37. So a 10 mcg/kg dose in a rat translates to approximately 10 × (6/37) ≈ 1.6 mcg/kg in a human. This conversion is approximate and intended for initial estimation in clinical trial design, not for direct application.

Why do some peptides require higher doses than others?

Dose requirements reflect several factors: receptor affinity (how tightly the peptide binds its target), signal amplification (how much downstream response each binding event produces), distribution volume (how widely the peptide disperses in the body), metabolic clearance rate (how quickly the peptide is degraded), and the density of target receptors in the tissue of interest. A peptide with high receptor affinity, strong signal amplification, and slow clearance (like Semax, active at microgram doses intranasally) requires far less mass than a peptide with lower affinity and rapid clearance.

What is a dose-response curve, and why does it matter?

A dose-response curve plots the magnitude of a biological effect (y-axis) against the dose of a compound (x-axis). It typically has a sigmoidal shape: no effect at very low doses, a steep increase over a narrow dose range, and a plateau at high doses. The curve matters because it reveals the minimum effective dose (where the effect first becomes detectable), the EC50 (the dose producing 50% of maximum effect — a standard measure of potency), and the maximum effective dose (beyond which increasing dose produces no additional effect). Without characterizing this curve, a researcher cannot distinguish a genuinely negative result (the compound does not work) from a dosing error (the compound was tested at a subthreshold or supratherapeutic dose).

Can I mix multiple peptides in the same syringe?

Mixing peptides in a single injection is technically possible but generally avoided in controlled research for several reasons. Chemical interactions between peptides in solution (cross-linking, competitive binding to excipients, pH incompatibility) may alter the stability or bioactivity of one or both compounds. If one peptide degrades faster than the other, the ratio changes over time, making dose calculations unreliable. Additionally, if an adverse reaction occurs, it becomes impossible to determine which peptide caused it. The standard research practice is to administer each peptide as a separate injection, at separate sites if given simultaneously, with independent concentration calculations and labeling.

Where can I find published dose ranges for specific peptides?

PubMed (https://pubmed.ncbi.nlm.nih.gov/) is the primary source for published dose ranges. Search for the peptide name plus terms like 'dose-response,' 'pharmacokinetics,' 'preclinical safety,' or 'toxicology.' For preclinical dose ranges, animal model studies provide the most specific data — search for the peptide name plus 'rat' or 'mouse' plus the tissue or system of interest. Clinical dose data, where it exists, is found in Phase I/II trial publications. Key databases include ClinicalTrials.gov (for registered trial protocols with dose information) and the FDA's approved labeling documents for approved peptide drugs (semaglutide, tirzepatide, liraglutide). The compound pages on CompoundGuide also reference published dose ranges for individual peptides.

Research Guide

Peptide Dosing Guide for Researchers

Research guide to peptide dosing: unit conversions, concentration math, SC volumes, route bioavailability, titration, and dose-response design.

Last updated Jul 15, 2026 14 min read

Dosing is where peptide research moves from theory to practice. A researcher can understand every molecular mechanism, know the target receptor, and have a clear hypothesis — but without accurate dosing, the experiment produces nothing reliable. The dose determines whether a compound reaches its target at a biologically active concentration or falls below the threshold of detectable effect.

Peptide dosing introduces specific challenges that small-molecule chemistry does not. Peptides are measured in micrograms (mcg), not milligrams. Injection volumes are measured in fractions of a milliliter. Concentration depends on the mass of peptide in a vial, the volume of solvent added during reconstitution, and the fraction of that volume drawn into a syringe. A miscalculation at any point in this chain produces a dose that is either too low to register biologically or too high to be scientifically meaningful.

This guide covers the three pillars of accurate peptide dosing in research: the units and arithmetic of concentration calculations, the range of doses used in published preclinical and clinical research for different peptide classes, and the principles of dose-response design — how researchers structure protocols to find the minimum effective dose and characterize the relationship between dose and biological response.

Nothing in this guide constitutes dosing advice for human subjects. All dose ranges referenced are drawn from published preclinical studies, clinical trials, or pharmacokinetic research. Researchers should consult institutional review boards and qualified pharmacologists when designing protocols involving peptide administration.

Overview

Peptide dosing operates on a different scale than most pharmaceutical research. Where a typical small-molecule drug might be dosed in hundreds of milligrams, many research peptides are active at microgram levels — a thousand-fold difference. This scale difference has practical consequences for every step of the dosing process.

The fundamental chain of peptide dosing begins with the lyophilized vial. A vial contains a known mass of peptide — typically 2 mg, 5 mg, 10 mg, or 15 mg — in dry powder form. During reconstitution, a measured volume of bacteriostatic water is added, creating a solution of known concentration. The researcher then draws a calculated volume from this solution to deliver a precise dose.

Three variables determine the delivered dose: the peptide mass in the vial (set by the manufacturer), the reconstitution volume (chosen by the researcher), and the injection volume (calculated from the desired dose and the resulting concentration). Changing any one of these variables changes the delivered dose, which is why the arithmetic must be explicit and verified.

Bioavailability — the fraction of administered peptide that reaches systemic circulation — varies by route and by molecule. Subcutaneous (SC) delivery is the workhorse route for research peptides, but absorption can differ by injection site, formulation, and molecular properties . Intramuscular delivery is broadly similar for many peptides. Oral bioavailability for unmodified peptides is typically very low due to enzymatic and permeability barriers . A few research peptides (notably gastric-origin compounds such as BPC-157 ) are studied orally in animal models, but this remains an exception rather than the rule . Intranasal delivery can bypass first-pass metabolism and is used for selected neuropeptides.

Concentration is not just math — it is also a practical constraint. Reconstituting a 5 mg vial in 0.5 mL produces a high concentration that supports small injection volumes, but may increase aggregation risk for some sequences. Reconstituting the same vial in 3 mL produces lower concentration and larger injection volumes that can approach common SC volume comfort limits (often discussed around 1–1.5 mL per site in the parenteral literature on injection-site tolerability) . Finding the optimal concentration for each peptide balances dosing precision, comfort, and stability.

Nothing in this guide constitutes dosing advice for human subjects. All ranges and examples are research-context observations for protocol design by qualified investigators under appropriate institutional oversight.

Units, Measurement, and Concentration Arithmetic

Peptide research uses three units of mass and two units of volume that researchers must convert fluently. Errors in unit conversion are the single most common source of dosing mistakes in peptide protocols.

Mass units: - Milligram (mg): 1 mg = 1,000 micrograms. This is the unit used on peptide vial labels. A "5 mg vial" contains 5,000 mcg of peptide. - Microgram (mcg or μg): 1 mcg = 0.001 mg. Most research peptide doses are expressed in micrograms. A dose of 250 mcg = 0.25 mg. - Nanogram (ng): 1 ng = 0.001 mcg = 0.000001 mg. Used in pharmacokinetic measurements of plasma concentration, not in dosing.

Volume units: - Milliliter (mL): The standard volume unit. A standard insulin syringe holds 1 mL (also labeled as 100 units on U-100 insulin syringes). - Milliunit on U-100 syringes: On a U-100 insulin syringe, each "unit" mark equals 0.01 mL (10 microliters). So 10 units = 0.1 mL, 50 units = 0.5 mL, and 100 units = 1.0 mL.

The core formula for concentration:

Concentration (mcg/mL) = Peptide mass (mg) × 1,000 / Reconstitution volume (mL)

Examples: - 5 mg peptide + 2 mL BAC water = 5,000 / 2 = 2,500 mcg/mL - 10 mg peptide + 1 mL BAC water = 10,000 / 1 = 10,000 mcg/mL - 2 mg peptide + 1 mL BAC water = 2,000 / 1 = 2,000 mcg/mL

The core formula for injection volume:

Injection volume (mL) = Desired dose (mcg) / Concentration (mcg/mL)

Examples (using 2,500 mcg/mL concentration): - 250 mcg dose → 250 / 2,500 = 0.1 mL (10 units on U-100 syringe) - 500 mcg dose → 500 / 2,500 = 0.2 mL (20 units) - 125 mcg dose → 125 / 2,500 = 0.05 mL (5 units)

Common reconstitution volumes and resulting concentrations:

| Vial Mass | + 1 mL | + 2 mL | + 3 mL | |-----------|--------|--------|--------| | 2 mg | 2,000 mcg/mL | 1,000 mcg/mL | 667 mcg/mL | | 5 mg | 5,000 mcg/mL | 2,500 mcg/mL | 1,667 mcg/mL | | 10 mg | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL |

The choice of reconstitution volume is a trade-off. Smaller volumes produce higher concentrations, which require smaller injection volumes (convenient for micro-dosing) but increase aggregation risk for some peptides. Larger volumes produce lower concentrations, requiring larger injection volumes but reducing aggregation. For most research peptides, 1–2 mL of bacteriostatic water per 5 mg vial is the standard range.

A critical but often overlooked detail: the total volume in the vial after reconstitution is not exactly equal to the volume of solvent added. The lyophilized powder occupies a small but non-zero volume. For precise work, researchers should account for this by measuring the total volume in the vial after complete dissolution rather than assuming it equals the solvent volume.

Research Dosing Ranges and Route-Dependent Bioavailability

Published preclinical and clinical research provides dose ranges for many research peptides. These ranges are not recommendations — they are observations from specific experimental contexts. Doses that produce effects in rodent models do not translate directly to other species due to allometric scaling differences (body surface area, metabolic rate, renal clearance).

** BPC-157 :** In the preclinical literature, BPC-157 has been studied across a wide dose range. A formal preclinical safety evaluation and multiple experimental models report doses spanning microgram-to-milligram per kilogram levels, administered intraperitoneally, subcutaneously, or orally . Mechanistic and tendon-healing studies commonly use low mcg/kg regimens and document cell-migration and growth-hormone receptor effects at research doses . Narrative reviews summarize the still-preclinical evidence base and delivery challenges .

BPC-157 has also been studied via oral delivery in animal models. If oral bioactivity is confirmed across endpoints, it would be mechanistically significant, because most peptides are degraded in the gastrointestinal tract . Hypotheses include gastric origin and relative resistance to acid/pepsin degradation, but formulation and translation remain open research problems .

** TB-500 ( Thymosin Beta-4 fragment):** Commercial “TB-500” products are typically actin-binding-domain fragments of thymosin β4 (Tβ4), not full-length Tβ4. Preclinical and translational literature on full-length Tβ4 describes multi-functional tissue-repair activity across dermal, angiogenic, and regenerative models . Rodent wound studies using Tβ4 peptides report mcg-range topical or systemic dosing depending on model . Human clinical experience, where available, is with full-length Tβ4 regimens rather than commercial fragment products — treat fragment dosing as non-equivalent unless a study specifies the exact sequence.

** GHK-Cu :** Dosing in the literature varies by route. Topical and formulation work with the copper tripeptide (GHK-Cu) uses low-percentage leave-on or wound-care concentrations, and reviews describe multi-pathway skin-regeneration effects . Subcutaneous animal regimens, when reported, are model-specific and should not be copied across species without allometric justification.

Bioavailability by route (typical order-of-magnitude framing for unmodified peptides):

| Route | Typical Bioavailability | Notes | |-------|------------------------|-------| | Subcutaneous (SC) | Variable; often substantial for many peptides | Injection site and formulation matter | | Intramuscular (IM) | Variable; often similar order to SC | Used for some formulations | | Intraperitoneal (IP) | High in rodents | Common in animal studies; not a human clinical route | | Intravenous (IV) | 100% (by definition) | Bypasses absorption; most precise but invasive | | Intranasal | Moderate for selected peptides | Bypasses first-pass; used for neuropeptides | | Oral | Typically very low for unmodified peptides | GI degradation and permeability barriers | | Topical | Highly variable | Depends on size, vehicle, and skin barrier |

Subcutaneous injection volume limits: Parenteral literature on injection-site pain and tolerability treats volume as a major local factor; practical guidance often keeps SC volumes near or below about 1–1.5 mL per site for comfort and more predictable absorption . Volumes well above this range increase pain, swelling, and absorption variability. When a dose requires a larger volume at standard concentration, researchers typically increase concentration (reconstitute with less solvent) or split the dose across two sites.

Allometric scaling note: When translating rodent doses to other species, the standard approach uses body surface area normalization (mg/m²) rather than simple mg/kg scaling. A dose of 10 mcg/kg in a 25 g mouse does not equal 10 mcg/kg in a 70 kg human. FDA guidance for allometric scaling provides conversion factors, though these are primarily designed for conventional drugs and may not fully account for peptide-specific pharmacokinetics.

Dose-Response Relationships and Protocol Design

The dose-response relationship describes how the magnitude of a biological effect changes with increasing dose. For most pharmacologically active compounds, this relationship follows a sigmoidal (S-shaped) curve: below a threshold dose, no measurable effect occurs; as dose increases, effect increases steeply; and above a ceiling dose, further increases produce diminishing or no additional effect.

Establishing the dose-response curve is one of the primary objectives of early-stage research. The key parameters are:

- Minimum effective dose (MED): The lowest dose at which a statistically significant effect is observed relative to control. - EC50 / ED50: The dose producing 50% of the maximum effect. This is the standard measure of a compound's potency. - Maximum effective dose: The dose above which no further increase in effect occurs. - Therapeutic index (in clinical contexts): The ratio between the toxic dose and the effective dose. For research peptides in preclinical stages, this is estimated from toxicology studies.

Practical protocol design for dose-response studies:

A standard dose-response study includes 3–5 dose groups plus a vehicle control, with 6–12 subjects per group (depending on expected variability). Doses are typically spaced at half-log intervals (e.g., 1, 3, 10, 30, 100 mcg/kg) to capture the shape of the curve without excessive group numbers.

Titration principles: Titration — the progressive increase of dose from a low starting point — is the standard approach in both clinical and preclinical contexts. The rationale is threefold:

1. Safety: Starting low and increasing gradually minimizes the risk of adverse reactions at supratherapeutic doses. 2. Individual variability: Biological systems vary. A dose that is subthreshold for one subject may be supratherapeutic for another. Titration allows each subject to find their individual response level. 3. Receptor dynamics: Many peptide receptors undergo desensitization (downregulation) when exposed to sustained high concentrations. Beginning with lower doses preserves receptor sensitivity.

The GLP-1 receptor agonists provide a well-documented titration model. In the STEP 1 obesity trial, once-weekly subcutaneous semaglutide was escalated from 0.25 mg through 0.5 mg and 1.0 mg to a 2.4 mg maintenance dose, with stepwise increases intended to improve gastrointestinal tolerability . Pharmacokinetic work on semaglutide describes albumin binding and a multi-day half-life that supports weekly dosing . Dual GIP/GLP-1 agonist tirzepatide was compared with semaglutide in SURPASS-2 using weekly dose-escalation schedules up to higher maintenance strengths . These clinical titration ladders illustrate the balance between maximizing effect and minimizing gastrointestinal adverse events — they are not templates for unapproved research peptides.

For research peptides without established clinical titration protocols, the titration principle still applies conceptually. Researchers typically begin with the lowest dose reported in the literature and increase incrementally across experimental cohorts, monitoring both primary endpoints and safety biomarkers at each step.

Frequency and duration considerations:

Peptide half-life determines dosing frequency. Short half-life peptides (minutes to hours) may require daily or twice-daily dosing to maintain target concentrations. Longer half-life peptides (days) may be dosed weekly. Engineered GLP-1 analogues such as semaglutide use fatty-acid / albumin-binding strategies to extend exposure from the minutes-scale half-life of native GLP-1 to roughly one week .

Dosing duration in preclinical studies typically ranges from acute (single dose, measuring immediate pharmacokinetics) to chronic (daily dosing for 2–12 weeks, measuring cumulative biological effects). The appropriate duration depends on the research question: acute pharmacokinetic studies characterize absorption and elimination, while chronic efficacy studies measure tissue-level changes that develop over weeks.

Putting Dosing Principles Together

Dosing accuracy, bioavailability knowledge, and dose-response design are interdependent. A researcher who understands concentration calculations but ignores bioavailability may deliver an effective dose at one route and a subtherapeutic dose at another using the same injection volume. A researcher who designs a dose-response study but uses inaccurate concentration math may place subjects in the wrong dose groups entirely.

The three components work as a system. Concentration arithmetic ensures the correct mass of peptide reaches the syringe. Bioavailability knowledge translates the administered dose into an estimate of what actually reaches systemic circulation. Dose-response design structures the experiment so that the relationship between dose and effect can be characterized with statistical rigor.

In practice, this means every peptide protocol should explicitly state: the peptide mass in the vial, the reconstitution volume and resulting concentration, the injection volume for each dose level, the route of administration with estimated bioavailability, and the dose expressed in both mcg and mcg/kg (for weight-normalized studies).

For researchers working with multiple peptides simultaneously — for example, BPC-157 and TB-500 in a tissue repair study — each peptide requires independent concentration calculations and potentially different reconstitution volumes. The convenience of reconstituting all vials with the same volume must be weighed against the optimal concentration for each peptide's stability and aggregation characteristics.

The research literature provides the starting point for all dosing decisions, but individual experimental conditions — species, strain, age, sex, health status, and the specific endpoint being measured — require researchers to calibrate doses within their own experimental system. Published dose ranges are guidelines, not prescriptions.

Frequently Asked Questions

: Micrograms (mcg or μg) and milligrams (mg) are metric mass units: 1 mg = 1,000 mcg. Most research peptides are dosed in the mcg range (100–1,000 mcg typical) rather than the mg range. IU (International Units) is a biological activity measurement used for insulin and some vitamins — it does not apply to most research peptides. The confusion arises because insulin syringes (marked in "units" where 100 units = 1 mL) are commonly used to inject peptides, but the syringe markings measure volume (0.01 mL per unit), not peptide mass. A researcher must calculate the appropriate volume based on their specific peptide concentration.
: Use this formula: Injection volume (mL) = Desired dose (mcg) / Concentration (mcg/mL). For example, if your concentration is 2,500 mcg/mL and your desired dose is 250 mcg: 250 / 2,500 = 0.1 mL. On a U-100 insulin syringe (where 100 units = 1 mL), this equals 10 units. Always verify your concentration calculation first: Concentration (mcg/mL) = Vial mass (mg) × 1,000 / Reconstitution volume (mL).
: Peptides are biologically active at much lower masses than small-molecule drugs. This reflects their mechanism: peptides bind to specific cell-surface receptors with high affinity, triggering signaling cascades at very low occupancy rates. A typical receptor-binding peptide may produce a maximal biological response when fewer than 10% of available receptors are occupied — a phenomenon known as receptor reserve. This means only a small number of peptide molecules (micrograms) are needed to activate a large downstream response. Small-molecule drugs, by contrast, often require milligram quantities because they work through enzyme inhibition or other mechanisms that demand higher molar concentrations.
: Yes — subcutaneous bioavailability is rarely 100%. For many peptides and proteins, a meaningful fraction of the administered dose may be degraded locally, bind tissue, or clear via lymph before reaching systemic circulation, and the magnitude varies with injection site and formulation [PMID: 34186147]. Published SC dose ranges already reflect that route. Consistency of technique, site, and depth across experimental groups is more important than chasing a theoretical 100% absorption figure.
: Parenteral literature on injection-site pain and absorption treats volume as a major local factor. Practical guidance commonly keeps subcutaneous volumes near or below about 1–1.5 mL per site to limit pain, swelling, and absorption variability [PMID: 31587143]. If a dose requires a larger volume at standard concentration, options include: (1) increase concentration with less reconstitution solvent, (2) split across two injection sites, or (3) use an intramuscular site that can tolerate larger volumes when the protocol allows.
: Simple mg/kg scaling does not work for interspecies dose conversion because metabolic rate, body surface area, and clearance rates scale allometrically — not linearly — with body mass. The FDA recommends body surface area (BSA) normalization using the formula: Human equivalent dose (mg/kg) = Animal dose (mg/kg) × (Animal Km / Human Km), where Km = body weight / BSA. For common research animals: mouse Km = 3, rat Km = 6, human Km = 37. So a 10 mcg/kg dose in a rat translates to approximately 10 × (6/37) ≈ 1.6 mcg/kg in a human. This conversion is approximate and intended for initial estimation in clinical trial design, not for direct application.
: Dose requirements reflect several factors: receptor affinity (how tightly the peptide binds its target), signal amplification (how much downstream response each binding event produces), distribution volume (how widely the peptide disperses in the body), metabolic clearance rate (how quickly the peptide is degraded), and the density of target receptors in the tissue of interest. A peptide with high receptor affinity, strong signal amplification, and slow clearance (like Semax, active at microgram doses intranasally) requires far less mass than a peptide with lower affinity and rapid clearance.
: A dose-response curve plots the magnitude of a biological effect (y-axis) against the dose of a compound (x-axis). It typically has a sigmoidal shape: no effect at very low doses, a steep increase over a narrow dose range, and a plateau at high doses. The curve matters because it reveals the minimum effective dose (where the effect first becomes detectable), the EC50 (the dose producing 50% of maximum effect — a standard measure of potency), and the maximum effective dose (beyond which increasing dose produces no additional effect). Without characterizing this curve, a researcher cannot distinguish a genuinely negative result (the compound does not work) from a dosing error (the compound was tested at a subthreshold or supratherapeutic dose).
: Mixing peptides in a single injection is technically possible but generally avoided in controlled research for several reasons. Chemical interactions between peptides in solution (cross-linking, competitive binding to excipients, pH incompatibility) may alter the stability or bioactivity of one or both compounds. If one peptide degrades faster than the other, the ratio changes over time, making dose calculations unreliable. Additionally, if an adverse reaction occurs, it becomes impossible to determine which peptide caused it. The standard research practice is to administer each peptide as a separate injection, at separate sites if given simultaneously, with independent concentration calculations and labeling.
: PubMed (https://pubmed.ncbi.nlm.nih.gov/) is the primary source for published dose ranges. Search for the peptide name plus terms like 'dose-response,' 'pharmacokinetics,' 'preclinical safety,' or 'toxicology.' For preclinical dose ranges, animal model studies provide the most specific data — search for the peptide name plus 'rat' or 'mouse' plus the tissue or system of interest. Clinical dose data, where it exists, is found in Phase I/II trial publications. Key databases include ClinicalTrials.gov (for registered trial protocols with dose information) and the FDA's approved labeling documents for approved peptide drugs (semaglutide, tirzepatide, liraglutide). The compound pages on CompoundGuide also reference published dose ranges for individual peptides.

Summary

Peptide dosing is fundamentally an exercise in precision. The microgram scale at which peptides are active means that small errors in unit conversion, concentration calculation, or injection volume produce proportionally large errors in delivered dose. Mastering the arithmetic — mass to concentration to volume — is a prerequisite for any peptide research protocol.

Bioavailability adds a second layer of complexity. The same mass of peptide delivered by different routes produces different systemic exposures. Subcutaneous injection, the workhorse of peptide research, delivers roughly half to most of the administered dose to circulation. Oral delivery, for most peptides, delivers very little. Understanding these differences is essential for interpreting published dose ranges and designing experiments that produce interpretable results.

Dose-response design provides the framework for moving from published literature to experimental practice. Starting with the minimum effective dose, escalating incrementally, and characterizing the full dose-response curve allows researchers to identify optimal dosing parameters for their specific experimental context.

As with all aspects of peptide research, the primary literature — accessible through PubMed — remains the most reliable source of dosing information. Published pharmacokinetic studies, toxicology reports, and dose-ranging experiments provide the empirical foundation on which protocol design rests. For reconstitution specifics, see the Peptide Reconstitution Guide. For storage and stability, see Peptide Storage & Handling.

I. Overview

II. Units, Measurement, and Concentration Arithmetic

III. Research Dosing Ranges and Route-Dependent Bioavailability

IV. Dose-Response Relationships and Protocol Design

V. Putting Dosing Principles Together

VI. Frequently Asked Questions

Frequently Asked Questions

VII. Summary

Overview

Units, Measurement, and Concentration Arithmetic

Research Dosing Ranges and Route-Dependent Bioavailability

Dose-Response Relationships and Protocol Design

Putting Dosing Principles Together

Frequently Asked Questions

Summary